Navigation Links
Hollis-Eden Pharmaceuticals Receives NASDAQ Notification Related to Minimum Bid Price
Date:9/16/2009

SAN DIEGO, Sept. 16 /PRNewswire-FirstCall/ -- Hollis-Eden Pharmaceuticals, Inc. (Nasdaq: HEPH), a leader in the development of a new class of small molecule compounds based on endogenous adrenal steroid hormones, today announced that it received a letter from The NASDAQ Stock Market on September 15, 2009.

The letter states that Hollis-Eden is not in compliance with Nasdaq Marketplace Rule 4450(a)(5) (the "Minimum Bid Price Rule") because its common stock had closed below $1.00 per share for 30 consecutive business days. The letter also states that in accordance with Nasdaq Marketplace Rules, Hollis-Eden has 180 days, or until March 15, 2010, to regain compliance with the Minimum Bid Price Rule. This letter has no immediate effect on the NASDAQ listing or trading of Hollis-Eden's common stock.

Hollis-Eden will regain compliance with the Minimum Bid Price Rule if the bid price of its common stock closes at $1.00 per share or more for a minimum of 10 consecutive business days before March 15, 2010. However, if Hollis-Eden does not regain compliance with the Minimum Bid Price Rule by March 15, 2010, the Nasdaq staff will provide Hollis-Eden with a written notification that its common stock is subject to delisting.

Hollis-Eden will monitor the bid price for its common stock and consider available options.

About Hollis-Eden Pharmaceuticals, Inc.

Hollis-Eden Pharmaceuticals, Inc. is developing a new series of small molecule compounds that are metabolites or synthetic analogs of endogenous hormones derived by the adrenal glands from the body's most abundant circulating adrenal steroid. Hollis-Eden's clinical drug development candidates include TRIOLEX(R) (HE3286), a next-generation compound currently in clinical trials for the tre
'/>"/>

SOURCE Hollis-Eden Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Hollis-Eden Pharmaceuticals Announces Appointment of Dr. James M. Frincke President and CEO
2. Vion Pharmaceuticals Pays Interest on 7.75% Convertible Senior Notes
3. China Biopharmaceuticals Holdings Announces Second Quarter 2007 Financial Results
4. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
5. XTL Biopharmaceuticals Announces Financial Results for the Six Months Ended June 30, 2007
6. Cadence Pharmaceuticals Reports Second Quarter 2007 Financial Results
7. Nabi Biopharmaceuticals to Present at Upcoming Industry Conferences
8. Anadys Pharmaceuticals Appoints Steve Worland, Ph.D. as President and Chief Executive Officer
9. Poniard Pharmaceuticals Announces Participation in Upcoming Conferences
10. NovaQuest Advances Virtual Development Model With Strategic Investment in TOPIGEN Pharmaceuticals
11. Drug Royalty Corporation (DRC) Announces Acquisition Regarding PEG-INTRON(R) From Enzon Pharmaceuticals, Inc. (ENZN)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/24/2014)... BETHESDA, Md. , Nov. 24, 2014 /PRNewswire/ ... property development company committed to the fostering and ... regarding  Spherix v. VTech Telecommunications Ltd.,  Case No. ... , Case No. 3:13-cv-03496-M, both in the United ... Texas . ...
(Date:11/23/2014)... 2014 Apiscent Labs, a privately ... chemical ingredients to the global pharmaceutical and flavor ... new website, Apiscent.com. , The Apiscent.com homepage welcomes ... design, easy navigation, rotating images and content focused ... out. , The company’s work in ...
(Date:11/22/2014)... 2014 During his lifetime Richard L. ... to surround himself with great people and take risks ... friends often marveled at his extraordinarily courageous attitude when ... and -- even with his death impending—that’s how he ... that would ultimately take his life. , Carrying on ...
(Date:11/22/2014)... Denver, Colo. (PRWEB) November 21, 2014 ... of proprietary cloud based analytics and scientific testing methodologies ... a commitment for a $750,000 line of credit from ... are extremely pleased to have secured this commitment from ... Chief Executive Officer of CannLabs. “This capital will help ...
Breaking Biology Technology:Markman Hearing Held as Scheduled in VTech and Uniden Cases 2Sherry Sharp, Wife of CarMax Founder, Richard Sharp, Accepts Seat on Board of Cure Alzheimer’s Fund 2Sherry Sharp, Wife of CarMax Founder, Richard Sharp, Accepts Seat on Board of Cure Alzheimer’s Fund 3CannLabs Secures $750,000 Line Of Credit 2
... JOLLA, Calif., Feb. 11 TorreyPines Therapeutics, Inc. ... oral administration of NGX426, an AMPA/kainate-type glutamate receptor ... and female subjects when dosed once daily for ... I trial demonstrating the safety and tolerability of ...
... 11 Advanced Life Sciences,Holdings, Inc. (Nasdaq: ... and commercialization of novel drugs in the therapeutic,areas of ... for the fourth quarter and full year ended December ... http://www.newscom.com/cgi-bin/prnh/20080218/ALSLOGO ) , The net ...
... 2009A team of Los Alamos researchers led by Victor ... multiple electronsis a real phenomenon in tiny semiconductor crystals ... that mimic carrier multiplication. The research, explained in a ... shows the possibility of solar cells that create more ...
Cached Biology Technology:First Multiple Dose Clinical Trial of TorreyPines Therapeutics' Oral Compound NGX426 Demonstrates Compound Is Safe and Well-Tolerated 2First Multiple Dose Clinical Trial of TorreyPines Therapeutics' Oral Compound NGX426 Demonstrates Compound Is Safe and Well-Tolerated 3First Multiple Dose Clinical Trial of TorreyPines Therapeutics' Oral Compound NGX426 Demonstrates Compound Is Safe and Well-Tolerated 4Advanced Life Sciences Announces 2008 Fourth Quarter and Full Year Financial Results 2Advanced Life Sciences Announces 2008 Fourth Quarter and Full Year Financial Results 3Advanced Life Sciences Announces 2008 Fourth Quarter and Full Year Financial Results 4Advanced Life Sciences Announces 2008 Fourth Quarter and Full Year Financial Results 5Advanced Life Sciences Announces 2008 Fourth Quarter and Full Year Financial Results 6Advanced Life Sciences Announces 2008 Fourth Quarter and Full Year Financial Results 7Advanced Life Sciences Announces 2008 Fourth Quarter and Full Year Financial Results 8Advanced Life Sciences Announces 2008 Fourth Quarter and Full Year Financial Results 9Advanced Life Sciences Announces 2008 Fourth Quarter and Full Year Financial Results 10Advanced Life Sciences Announces 2008 Fourth Quarter and Full Year Financial Results 11Advanced Life Sciences Announces 2008 Fourth Quarter and Full Year Financial Results 12Research highlights potential for improved solar cells 2Research highlights potential for improved solar cells 3
(Date:11/6/2014)... because of metastasis, yet progress in preventing and ... "It,s been particularly challenging to design drugs that ... in systems biology at Harvard Medical School. ... they,ve already metastasized." , Gujral and colleagues have ... researchers better understand how metastasis begins. Their findings ...
(Date:11/5/2014)... show great diversity in their ability to identify scents ... differ in their perceptual evaluation of odors, with women ... , Sex differences in olfactory detection may play ... connected to one,s perception of smell, which is naturally ... superiority has been suggested to be cognitive or emotional, ...
(Date:11/4/2014)... newly published research study examining only marketing directed ... fast food restaurants has found that the majority ... exposed to such marketing tactics. , Authored by ... colleagues, the study is the first to examine ... and exterior of fast food restaurants and its ...
Breaking Biology News(10 mins):Migration negation 2Migration negation 3The female nose always knows: Do women have more olfactory neurons? 2Fast food marketing for children disproportionately affects certain communities 2Fast food marketing for children disproportionately affects certain communities 3
... NeuralIQ, a developer of,cyber intelligence tools for information ... team, headed by the appointment of,Donnie Blanks as ... President of Sales and strategy for Perot,Systems, government ... the,company continues to advance its industry presence and ...
... Pa. -- A little known fungus tucked away in ... munch through the hardest of woods according to a ... could lead to innovative methods of controlling the invasive ... down plant biomass for generating biofuels. Microbes in ...
... Atlantic Ocean shows that hot, dry air associated with ... contributor to the quieter-than-expected 2007 hurricane season. Factors ... in a season, including El Nio, sea surface temperatures, ... [identify what agency made these forecasts; otherwise it might ...
Cached Biology News:NeuralIQ Expands Global Leadership Team, Names Donnie Blanks CEO 2NeuralIQ Expands Global Leadership Team, Names Donnie Blanks CEO 3Novel fungus helps beetles to digest hard wood 2Novel fungus helps beetles to digest hard wood 32007 hurricane forecasts took blow from winds and Saharan dry, dusty air 22007 hurricane forecasts took blow from winds and Saharan dry, dusty air 3
...
... PGE1-d4 contains 4 deuterium atoms at ... It is intended for use as an ... by GC- or LC-mass spectrometry. PGE1 is ... (DGLA), but it is virtually undetectable in ...
Direct ELISA Assay Diluent, 10 L...
... ZMD.474. Immunogen: Synthetic peptide derived ... mouse junctophilin-3. Specificity: Specific for ... protein. Reactivity: Mouse (positive controls: ... and heart tissues). Applications: Western ...
Biology Products: